Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Abstract Background The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. One of the vaccines approved against COVID-19 is the BNT162b2 mRNA COVID-19 vaccine (Pfizer/BioNTech). Case presentation We present the ca...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yamato Nishiguchi, Hirofumi Matsuyama, Kuniko Maeda, Akihiro Shindo, Hidekazu Tomimoto
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Miller fisher syndrome Guillain–Barré syndrome SARS-CoV-2 COVID-19 Vaccination Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/fee589abc59e4fef94e0621dbf856380
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fee589abc59e4fef94e0621dbf856380
record_format	dspace
spelling	oai:doaj.org-article:fee589abc59e4fef94e0621dbf8563802021-11-21T12:09:25ZMiller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination10.1186/s12883-021-02489-x1471-2377https://doaj.org/article/fee589abc59e4fef94e0621dbf8563802021-11-01T00:00:00Zhttps://doi.org/10.1186/s12883-021-02489-xhttps://doaj.org/toc/1471-2377Abstract Background The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. One of the vaccines approved against COVID-19 is the BNT162b2 mRNA COVID-19 vaccine (Pfizer/BioNTech). Case presentation We present the case of a 71-year-old man with no history of the SARS-CoV-2 infection or any recent viral or bacterial illnesses who presented with bilateral oculomotor palsy and limb ataxia after BNT162b2 mRNA COVID-19 vaccination. The diagnosis of Miller Fisher syndrome (MFS) was established based on physical examination, brain magnetic resonance imaging (MRI), cerebrospinal fluid analysis (CSF), and positron emission tomography (PET). There was no evidence of other predisposing infectious or autoimmune factors, and the period from COVID-19 vaccination to the appearance of neurological symptoms was similar to that of other vaccines and preceding events, such as infection. Conclusion Guillain–Barré syndrome (GBS) and its variants after COVID-19 vaccination are extremely rare. Note that more research is needed to establish an association between MFS and COVID-19 vaccines. In our opinion, the benefits of COVID-19 vaccination largely outweigh its risks.Yamato NishiguchiHirofumi MatsuyamaKuniko MaedaAkihiro ShindoHidekazu TomimotoBMCarticleMiller fisher syndromeGuillain–Barré syndromeSARS-CoV-2COVID-19VaccinationNeurology. Diseases of the nervous systemRC346-429ENBMC Neurology, Vol 21, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Miller fisher syndrome Guillain–Barré syndrome SARS-CoV-2 COVID-19 Vaccination Neurology. Diseases of the nervous system RC346-429
spellingShingle	Miller fisher syndrome Guillain–Barré syndrome SARS-CoV-2 COVID-19 Vaccination Neurology. Diseases of the nervous system RC346-429 Yamato Nishiguchi Hirofumi Matsuyama Kuniko Maeda Akihiro Shindo Hidekazu Tomimoto Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
description	Abstract Background The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. One of the vaccines approved against COVID-19 is the BNT162b2 mRNA COVID-19 vaccine (Pfizer/BioNTech). Case presentation We present the case of a 71-year-old man with no history of the SARS-CoV-2 infection or any recent viral or bacterial illnesses who presented with bilateral oculomotor palsy and limb ataxia after BNT162b2 mRNA COVID-19 vaccination. The diagnosis of Miller Fisher syndrome (MFS) was established based on physical examination, brain magnetic resonance imaging (MRI), cerebrospinal fluid analysis (CSF), and positron emission tomography (PET). There was no evidence of other predisposing infectious or autoimmune factors, and the period from COVID-19 vaccination to the appearance of neurological symptoms was similar to that of other vaccines and preceding events, such as infection. Conclusion Guillain–Barré syndrome (GBS) and its variants after COVID-19 vaccination are extremely rare. Note that more research is needed to establish an association between MFS and COVID-19 vaccines. In our opinion, the benefits of COVID-19 vaccination largely outweigh its risks.
format	article
author	Yamato Nishiguchi Hirofumi Matsuyama Kuniko Maeda Akihiro Shindo Hidekazu Tomimoto
author_facet	Yamato Nishiguchi Hirofumi Matsuyama Kuniko Maeda Akihiro Shindo Hidekazu Tomimoto
author_sort	Yamato Nishiguchi
title	Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
title_short	Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
title_full	Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
title_fullStr	Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
title_full_unstemmed	Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
title_sort	miller fisher syndrome following bnt162b2 mrna coronavirus 2019 vaccination
publisher	BMC
publishDate	2021
url	https://doaj.org/article/fee589abc59e4fef94e0621dbf856380
work_keys_str_mv	AT yamatonishiguchi millerfishersyndromefollowingbnt162b2mrnacoronavirus2019vaccination AT hirofumimatsuyama millerfishersyndromefollowingbnt162b2mrnacoronavirus2019vaccination AT kunikomaeda millerfishersyndromefollowingbnt162b2mrnacoronavirus2019vaccination AT akihiroshindo millerfishersyndromefollowingbnt162b2mrnacoronavirus2019vaccination AT hidekazutomimoto millerfishersyndromefollowingbnt162b2mrnacoronavirus2019vaccination
_version_	1718419222917283840

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination

Ejemplares similares